ABSTRACT
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) is a complex retrovirus (1) . Its genome contains five 5' splice sites and >10 3' splice sites. During virus replication, the HIV-1 9.2 kb primary transcript is spliced to >40 different singly and multiply spliced mRNA species (2) (3) (4) (5) (6) . The singly spliced mRNAs encode Env, Vif, Vpr and Vpu whereas the multiply spliced mRNAs encode Tat, Rev and Nef (5, 7, 8) . The unspliced mRNA is used as message for Gag and Pol and is packaged into virions. Successful retroviral replication requires that a balance of these mRNAs be maintained. This is achieved by regulating both altemative splicing and transport of mRNA species (9) .
The splicing of HIV-1 pre-mRNA is dependent on the host splicing machinery. In metazoan cells, this process involves the cleavage and joining of the 5' splice site and the 3' splice site (3'ss) by the spliceosome which is assembled through a series of protein-protein and protein-RNA interactions (10, 11) . Retroviral replication requires that the single full-length primary RNA transcript be spliced inefficiently (12, 13) . A number of cis-acting elements within the HIV-1 pre-mRNA have been shown to regulate splicing. These include the polypyrimidine tract and branch point of the 3'ss (14) (15) (16) , exon splicing enhancer and silencers, and downstream 5' splice sites (16) (17) (18) . During the early stage of HIV-1 replication, doubly spliced tat, rev and nef mRNAs are constitutively transported from the nucleus into the cytoplasm and translated independently of the expression of any viral proteins. Tat and Rev are both essential proteins for viral replication. Tat is an trans-activator which binds to the cis-acting element TAR and enhances the transcription of viral RNA (19) (20) (21) . Unspliced and singly spliced HIV-1 RNAs are retained in the nucleus in the absence of the Rev protein. After the accumulation of sufficient Rev protein, HIV-1 replication switches to the late stage in which the Rev protein binds to the Rev response element (RRE) located in the env gene. This facilitates the nuclear to cytoplasmic transport and the expression of singly and unspliced RNAs (22) (23) (24) (25) .
We and others have previously demonstrated that tat lrev exon 3 splicing is regulated by a suboptimal 3' splice site as well as by an exon splicing enhancer (ESE) and splicing silencer (ESS) within tal lrev exon 3 (18, 26 ). An ESS is also present within tal exon 2. This element acts selectively to inhibit splicing at the upstream 3' splice site flanking this tal exon. The ESS has been defined by linker-scanner mutagenesis to a 20 nucleotide (nt) RNA sequence spanning the C-terminal region of vpr and the N-terminal tal coding region. It has also been demonstrated that the ESS sequence in lat exon 2 functions as a splicing silencer when placed downstream of the heterologous Rous sarcoma virus (RSV) src 3' splice site. The addition of competitor RNA containing the ESS to a splicing reaction with HIV-1 RNA substrates containing the ESS causes a specific relief of inhibition at the upstream 3' splice site (18) . This led us to propose that this element represents a binding site for a negative-acting cellular factor present in HeLa cell nuclear extract that inhibits splicing at an early step (18) . The studies in this report were carried out to further define this putative cellular factor binding site. 
MATERIALS AND METHODS

Plasmid constructions
All mutations were made by PCR-mediated site-directed mutagenesis (27) . The regions corresponding to the PCR products were sequenced to confirm that no misincorporation mutations had occurred. pHS1-X has been described previously (17) and was used as the parent plasmid for all mutant HIV-1 minigene constructs. These include pESS4142, pESS4344, pESS4546, pESS4748, pESS4950, pESS5152, pESS53554, pESS5556, pESS5758, pESS5960, pESS4748+ESS5152, pTat3'C, pAESS and pTat3/C+AESS. pAESS was previously named pHS-1ASRE (17) . They were all linearized with Hindffi at nt 6026 of pNL4-3 (GenBank accession no. M19921) and used as templates to synthesize RNA substrates by in vitro transcription. pRSVWT has been described previously (28) and was used to make all the RSV-derived minigene constructs which include pECS, pECC, pECUS, pECUC, pECDS, pECDC, pESSS, pESSC, pSrc3'C, pSrc3'C+ESSS and pSrc3'C+ESSC. pSrc3'C was previously called pRSAP-1 (28). All plasmids derived from pRSVWT were linearized with NaeI at nt 7169 of RSV Prague A and used to synthesize RNA substrates.
In vitro RNA splicing RNA substrates of pHS1-X and its derivatives were synthesized by in vitro transcription with T3 RNA polymerase. RNA substrates of pRSV7169 and its derivatives were synthesized by in vitro transcription with SP6 RNA polymerase. HeLa cell nuclear extracts were prepared and splicing reactions were performed as previously described (17, 29, 30) . The products of the splicing reactions were separated on 4% 7 M urea-polyarylamide gels. At least three gels for each substrate were scanned and quantitated using an AMBIS image analysis system (AMBIS, Inc., San Diego, CA). The amounts of product were calculated on the basis of the uridine number of the RNA species and expressed as splicing efficiency relative to the wild-type to correct for different splicing efficiencies obtained with different HeLa nuclear extract preparations.
RESULTS
The activity of the ESS maps to a 10 nt core sequence
We have previously demonstrated that a 20 nt ESS element (from fit 5841 to 5860), present within the tat exon 2 of the HIV-1 strain NL4-3, acts to selectively inhibit splicing at the upstream 3' splice site (3'ss #3) flanking this tat exon (17, 18) . To further characterize this ESS, we created 2 nt substitution mutations shown in Figure lA to determine the importance of the individual bases within the element. The RNA substrates containing the mutations were spliced in vitro using HeLa cell nuclear extracts. As can be seen in Figure 1B and D, mutations within the central eight nucleotides (ESS4748, ESS'4950, ESS5152 and E5S5354) resulted in significant increases in splicing indicating that these nucleotides were essential for the activity of the ESS. However, the 2-3-fold increases obtained with these 2 nt substutution mutations were lower than the -4-fold increase obtained when the entire ESS region was deleted (17,18; see Fig. 3C , compare WT to AESS). Therefore, we determined the effect of a double 2 nt mutation ESS4748+ESS5152 (Fig. 1A) . As shown in Figure 1C and D, the level of splicing of this mutant substrate was increased to a level comparable to the ESS deletion mutant (AESS). On tl other hand, mutant substrates ESS4142, ESS4546, ESS555 ESS5758 and ESS5960 were spliced with efficiencies that wei within experimental error, the same as wild-type. Based on the results together with our previously published data (18) , v concluded that the activity of the ESS was contained within tl core sequence CUAGACUAGA (nt 5846-5855). Mutant su strate ESS4344 was spliced with a somewhat lower efficiem than wild-type. This indicates that in the HIV-1 context ti upstream flanking sequence may modulate the negative activi of the core element.
The ESS core sequence is sufficient to inhibit splicing when inserted downstream from the 3'ss of the heterologous RSV src gene Having localized the negative activity of the ESS element with tat exon 2 to a 10 nt core sequence, we next asked whether th core element was sufficient to inhibit splicing when placed in heterologous context and whether there is an effect of the flankir sequences on the ESS activity of the core element. To this end, series of RSV src gene substrates were created containing the ES core sequence and flanking sequences downstream of the src splice site. The corresponding RNA substrates were spliced vitro. As shown in Figure 2A , four pairs of insertion mutatico were constructed. One member of each pair contained ti sequence; the other contained the complement of this sequence which the purines were changed to their correspondir complementary pyrimidines and vice versa. All the insertioi were placed at the same distance relative to the upstream src splice site as was the ESS in the HIV-1 context. Substrates EC and ECC contained only the 10 nt core sequence of the HIV-ESS. ECUS and ECUC contained the ESS core and its immediai upstream 5 nt sequence whereas ECDS and ECDC contained ESS core plus its immediate downstream 5 nt sequence. ESS and ESSC contained the 20 nt long ESS or its complement an served as controls. Splicing of RSV src substrates ECS, ECU; ECDS and ESSS was only about half as efficient as wild-type c substrates containing the corresponding complementar sequences (ESC, ECUC, ECDC and ESSC) ( Fig. 2B and C These results indicate that the ESS core sequence CUAGACUA GA is sufficient to inhibit splicing at the heterologous src 3'ss an that the upstream and downstream flanking sequences do ric significantly affect the activity of the ESS. The tat exon 23' splice site contains a weak polypyrimidine tra and a nonconsensus 3'ss sequence. To determine if the negativ activity of the ESS requires a suboptimal upstream 3'ss, w synthesized RNA substrates with a consensus polypyrimidin tract and 3' splice site sequence and tested them in an in vitr splicing system (Fig. 3A) . The effect of the improved 3'ss wo first tested in the context of an intact downstream ESS elemen This substrate (Tat3'C) demonstratecl a 3-fold increase in splicin, efficiency compared to a substrate containing the wild type '2 splice site which was splicecl very inefficiently ( Fig. 3B and C: Thus, splicing at tat exon 2, in addition to the negative effect o the ESS, is regulated by the presence of a weak 3' ss which is agreement with a previous study (15 strated a 4-fold increase in splicing efficiency at tat exon 2 3'ss compared to wild-type substrate ( Fig. 3B and C) . To determine if the ESS element could act to inhibit splicing at the consensus optimized splice site, we studied substrate Tat3'C+AESS which has both the improved 3'ss mutation and the deleted ESS element. The splicing efficiency of this substrate was increased an additional 2-fold at tat exon2 3'ss compared to the splicing efficiency of substrate Tat 3'C ( Fig. 3B and C) . This significant increase in splicing at the improved tat 3' splice site when the ESS element was deleted indicated that the ESS element stilt had a negative effect on splicing when placed downstream of a consensus 3'ss. However, the magnitude of the inhibition was less compared to a 4-fold effect observed for the wild-type substrate (compare WT to AESS; Tat3'C to Tat3'C+AESS). This demonstrated that the negative control of the ESS element on the splicing efficiency of the tat exon 2 3'ss is not absolutely dependent on a weak 3'ss but that the regulatory-control of the ESS element is more efficient in the context of a weak 3'ss.
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The ESS acts to inhibit splicing at the optimized 3'ss of RSV src gene
To further test the effect of the HIV-1 tat exon 2 ESS on a consensus upstream 3' splice site, we inserted both the ESS and its corresponding complementary sequence downstream of an optimized avian retrovirus RSV src 3' splice site. The optimize< src 3'ss has a consensus branch point and consensus polypyrimi dine tract (Fig. 4A) (31) . The distance of the ESS relative to sr■ 3'ss was identical to the distance from the tat 3' splice site in th( HIV-1 tat exon 2 context. As previously reported, the polypyrimi dine tract of src 3'ss is suboptimal and the improved polypyrimi dine tract resulted in 1.7-fold increase of src splicing compare( to wild-type substrate ( Fig. 4B and C; compare Src3'C and wil( type) (28). When the ESS was inserted downstream of tb optimized src 3'ss, the splicing efficiency at src 3'ss was reduce( to approximately wild-type level ( Fig. 4B and C ; compar Src3'C+ESSS and Src3'C). However, if the ESS complementar. sequence was inserted, the splicing efficiency at src 3'ss wa increased to levels seen with the optimized substrate containin; no insertions ( Fig. 4B and C ; compare Src3'C+ESSC Src3'C). These results demonstrated that the ESS was stil functional when placed downstream of an optimizel heterologous 3'ss. However, the magnitude of the effect wa reduced compared to the activity of the ESS in the context of suboptimal 3' splice site.
DISCUSSION
We have carried out point mutagenesis across the ESS sequenc within HIV-1 tat exon 2 and have shown that the activity of th ESS maps to 10 nt CUAGACUAGA core sequence. This sequence is necessary for the negaiive ESS activity in the homologous HIV-1 context and also is sufficient to inhibit splicing at an upstream 3'ss when placed downstrearn of a heterologous RSV src 3'ss. In the context of the HIV-1 genome, the behavior of substrate ESS4344 suggests that the 5' flanking sequence may have an effect on the activity of the core ESS element (Fig. 1D) . In the context of the src exon, however, the flanking sequences upstream and downstream of the ESS core sequence do not appear to significantly affect its activity. Based on these results and other results from our laboratory, we hypothesize that the core sequence may represent the binding site for a putative cellular factor (18) .
We and others have previously shown that an ESS element is also present within tatlrev exon 3 (18, 26) . This ESS is juxtaposed to a purine-rich ESE to form a bipartite element regulating splicing at the upstream tatlrev exon 3 3'ss. The ESS element within tatlrev exon 3 was mapped to a region containing the sequence AGAUCCAUUCGAUUAGUGAA (the sequences underlined are homologous to sequences in the ESS within tat exon 2). We have shown in this report that the homologous sequence in the 5' part of the element (AGAUCC) does not appear to play a significant role in the inhibitory activity of the tat exon 2 ESS. However, the 3' region of the tat exon 2 element (CUAGACUAGA) contains some homology to the sequence in tatl rev exon 3. A potential consensus sequence can be identified as PyUAG and there are two copies of this sequence in the tat exon 2 ESS of the HIV-1 NL4-3 strain. Further point mutagenesis of the ESS within the tatlrev exon 3 will be necessary to determine the significance of these sequence homologies. The existence of two elements is consistent with the increase in splicing obtained when we combined the two mutations ESS4748 and ESS5152 (Fig. 1D) . Each of these mutations would be expected to disrupt only one of the two consensus sequences. The ESS core sequence is not absolutely conserved in all HIV-1 strains. Interestingly, however, most sequenced strains contain at least one copy of a PyUAG motif at the same site in the tat exon 2. Sequence variations in this region of the HIV-1 genome could potentially affect the activity of the ESS resulting in different levels of tat RNA splicing.
Several other exon sequences have been demonstrated to act negatively on splicing at the upstream 3'ss. A sequence UAGG, present in the alternative exon K-SAM in the fibroblast growth factor receptor-2 gene, has been shown to have a negative effect on splicing at the upstream K-SAM 3' splice site (32, 33) . It is of interest that the HIV-1 tat exon 2, the HIV-1 tatlrev exon 3 and the K-SAM element all contain at least one copy of the nonsense codon UAG. It has been concluded from several previous in vivo studies that the presence of premature termination codon within an exon causes inhibition of splicing (34, 35) . Furthermore, Aoufouchi et al. have described a cell-free system from a human B cell line in which splicing of mouse immunoglobulin mRNA substrates with premature termination codons is inhibited (36) . If the splicing inhibitory activity in the HIV-1 tat exon 2 results from the presence of nonsense codons, it would be expected that changing the UAG codons to other tennination codons UAA and UGA should not affect its activity. These experiments are in progress in our laboratory. Similar studies carried out by Del Gatto et al. (33) with the K-SAM exon showed that splicing was no longer inhibited when such changes were made. These results suggested that in the case of the K-SAM element, splicing C WT Src3'C Src3.C+ESSS Src3r+ESSC inhibition did not result from the UAG acting as a stop condon. Other identified exon splicing silencers appear to have little similarity to the ESS core sequence within the tat exon 2 and do not contain a UAG sequence. The ESS located downstrearn of bovine papillomavirus type I nucleotide 3225 3' splice site is a pyrimidine-rich region (37); the human fibronectin EDA exon ESS has a CAAGG motif (38) . These sequence dissimilaritie among the different ESS elements identified to date suggest thai inhibition of splicing at upstream 3' splice sites may be caused binding of a number of different factors. Retroviruses require weak 3' splice sites to balance the splicing of different genes during their replication. In Rous sarcoma virus both env and src 3' splice sites are suboptimal and they ar( essential for the successful replication of the vim (13, 28, 31, 39, 40) . For HIV-1 all the 3' splice sites are inefficien and it has been proposed that the inefficient 3' ss contributes to th( regulation of HIV-1 alternative splicing (15) . Our results havc confirmed that the tat exon 2 3'ss has a suboptima polypyrimidine tract since the splicing efficiency at this site i; increased by mutation of interspersed purines in the tract pyrimidines. Thus, splicing at the tat exon 2 3'ss is regulated botl by a suboptimal 3'ss and by an ESS located within this exon. Ou results have shown that when the ESS is downstream o suboptimal 3' splice sites either in its homologous position o when present in a heterologous exon, the level of inhibition higher compared to the effect of ESS downstream from consensus 3'ss. Therefore, the strength of the HIV-1 lat exon 3'ss and the ESS both appear to control the overall splicinj efficiency at the tat 3'ss insuring that the appropriate amount o tal mRNA is produced dwing virus infection. 
